Victory Capital Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-20,780
| Closed | -$987K | – | 2424 |
|
|
2025
Q3 | $987K | Sell |
20,780
-31,050
| -60% | -$1.5M | ﹤0.01% | 1843 |
|
|
2025
Q2 | $2.77M | Buy |
51,830
+16,714
| +48% | +$759K | ﹤0.01% | 1500 |
|
|
2025
Q1 | $1.42M | Buy |
35,116
+27,881
| +385% | +$1.18M | ﹤0.01% | 1642 |
|
|
2024
Q4 | $201K | Sell |
7,235
-135
| -2% | -$4.09K | ﹤0.01% | 2235 |
|
|
2024
Q3 | $211K | Buy |
+7,370
| New | +$192K | ﹤0.01% | 2214 |
|
|
2024
Q1 | – | Sell |
-13,880
| Closed | -$324K | – | 2476 |
|
|
2023
Q4 | $324K | Sell |
13,880
-179,572
| -93% | -$3.54M | ﹤0.01% | 2104 |
|
|
2023
Q3 | $9.78M | Sell |
193,452
-104,120
| -35% | -$4.85M | 0.01% | 1027 |
|
|
2023
Q2 | $13.9M | Buy |
297,572
+93,990
| +46% | +$4.31M | 0.02% | 913 |
|
|
2023
Q1 | $7.79M | Buy |
203,582
+199,495
| +4,881% | +$8.89M | 0.01% | 1101 |
|
|
2022
Q4 | $224K | Sell |
4,087
-15,127
| -79% | -$648K | ﹤0.01% | 2243 |
|
|
2022
Q3 | $654K | Sell |
19,214
-702
| -4% | -$10.7K | ﹤0.01% | 1929 |
|
|
2022
Q2 | $188K | Sell |
19,916
-10
| -0.1% | -$104 | ﹤0.01% | 2365 |
|
|
2022
Q1 | $209K | Buy |
19,926
+717
| +4% | +$12.6K | ﹤0.01% | 2398 |
|
|
2021
Q4 | $406K | Sell |
19,209
-2,763
| -13% | -$61.3K | ﹤0.01% | 2259 |
|
|
2021
Q3 | $491K | Buy |
21,972
+31
| +0.1% | +$702 | ﹤0.01% | 2184 |
|
|
2021
Q2 | $544K | Sell |
21,941
-1,021
| -4% | -$28.7K | ﹤0.01% | 2164 |
|
|
2021
Q1 | $666K | Sell |
22,962
-1,058
| -4% | -$32K | ﹤0.01% | 2072 |
|
|
2020
Q4 | $620K | Sell |
24,020
-1,022
| -4% | -$28.4K | ﹤0.01% | 1973 |
|
|
2020
Q3 | $771K | Sell |
25,042
-8,666
| -26% | -$303K | ﹤0.01% | 1816 |
|
|
2020
Q2 | $840K | Sell |
33,708
-34,180
| -50% | -$781K | ﹤0.01% | 1806 |
|
|
2020
Q1 | $1.44M | Buy |
67,888
+66,280
| +4,122% | +$1.42M | ﹤0.01% | 1726 |
|
|
2019
Q4 | $36K | Sell |
1,608
-1,021
| -39% | -$21.1K | ﹤0.01% | 2613 |
|
|
2019
Q3 | $60K | Buy |
2,629
+1,021
| +63% | +$23.8K | ﹤0.01% | 2598 |
|
|
2019
Q2 | $31K | Buy |
+1,608
| New | +$30.5K | ﹤0.01% | 1775 |
|
Other funds holding AKRO
Victory Capital Management's AKRO Position: Q4 2025 in Review
Victory Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,780 shares — an estimated $987K sold.
Victory Capital Management first reported a position in AKRO in Q2 2019 and held it in 24 quarters. The position peaked at $13.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Victory Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Victory Capital Management sold 20,780 Akero Therapeutics shares in Q4 2025, an estimated $987K.
- Victory Capital Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 24 quarters.
- Victory Capital Management's Akero Therapeutics position peaked at $13.9M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Victory Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.